1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
243.51 USD   -0.55%
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Big Biotech Firms Have Several Catalysts Lined Up, UBS Says

04/27/2022 | 04:14pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.55% 243.51 Delayed Quote.9.07%
BIOGEN INC. -5.18% 202.51 Delayed Quote.-11.67%
BRISTOW GROUP INC. 0.66% 24.42 Delayed Quote.-27.00%
GILEAD SCIENCES, INC. -0.99% 62.21 Delayed Quote.-13.12%
VERTEX PHARMACEUTICALS -3.88% 276.17 Delayed Quote.33.22%
VERTEX, INC. -1.04% 11.45 Delayed Quote.-25.52%
All news about AMGEN INC.
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference..
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
06/08BEHIND ONE BIOTECH'S WATER CONSERVAT : Saving Every Drop
PU
06/08TRANSCRIPT : Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-20..
CI
06/07Amgen - FDA APPROVES RIABNI (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN (RITUXIMAB), FOR ..
AQ
06/06NEW BPCIA COMPLAINT : Genentech Files Suit Against Tanvex Regarding Its Proposed Herceptin..
AQ
06/06Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis
MT
06/06FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ..
PR
06/06Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 214 M - -
Net income 2022 6 802 M - -
Net Debt 2022 26 905 M - -
P/E ratio 2022 19,3x
Yield 2022 3,12%
Capitalization 130 B 130 B -
EV / Sales 2022 5,99x
EV / Sales 2023 5,69x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 243,51 $
Average target price 246,51 $
Spread / Average Target 1,23%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.9.07%131 077
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-14.92%272 090
ABBVIE INC.12.51%269 202